COMMUNIQUÉS West-GlobeNewswire

Surgery Partners, Inc. Announces Fourth Quarter and Full Year 2017 Earnings Release Date and Conference Call

22/02/2018 - 13:00

NASHVILLE, Tenn., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ: SGRY ) ("Surgery Partners" or the "Company"), a leading provider of surgical services, today announced that the Company will release [...]

Natus Announces $30 Million Share Repurchase Program

22/02/2018 - 13:00

PLEASANTON, Calif. , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: BABY ) announced that its Board of Directors has authorized the repurchase of up to $30 million of the Company's common stock. [...]

DiaMedica Announces First Enrollment in its PHASE 2 “REMEDY” TRIAL for Acute Ischemic Stroke

22/02/2018 - 13:00

DM199 may offer an effective and safe treatment with a significantly longer treatment window (24 hours) compared to the current standard of care REMEDY trial lead by prominent neurologist Dr. Bruce Campbell, its [...]

RedHill Biopharma Provides Fourth Quarter and Full-Year 2017 Investor Update

22/02/2018 - 13:00

Key Highlights: Top-line results from the Phase III study with RHB-104 for Crohn’s disease expected in mid-2018 Top-line results from the confirmatory Phase III study with TALICIA ® for H. pylori infection expected in [...]

LHC Group and Almost Family Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Merger

22/02/2018 - 13:00

LAFAYETTE, La. and LOUISVILLE, Ky., Feb. 22, 2018 (GLOBE NEWSWIRE) -- LHC Group, Inc. (“LHC Group”) (NASDAQ: LHCG ) and Almost Family, Inc. (“Almost Family”) (NASDAQ: AFAM ) announced today that the waiting period under [...]

Loxo Oncology to Announce Fourth Quarter and Year-End 2017 Financial Results

22/02/2018 - 12:45

STAMFORD, Conn., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO ), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers [...]

Achillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial Results

22/02/2018 - 12:05

Corporate restructuring expected to enable Achillion to focus on goal of advancing its clinical and late-stage preclinical portfolio while maintaining a strong balance sheet Joseph Truitt, Chief Operating Officer, [...]

Biohit GastroPanel® test helps reducing unnecessary gastroscopies in pre-operative evaluation of the patients referred for bariatric surgery

22/02/2018 - 12:00

Biohit Oyj Press release, 22nd February, 2018 at 1:00 p.m. local time (EET) Bariatric (obesity) surgery has become increasingly common in Western countries as the ultimate means to reduce the excess weight in patients [...]

Sernova’s Cell Pouch Regenerative Medicine Clinical Trial for Patients with Type 1 Diabetes Supported with Continuous Glucose Monitoring Systems

22/02/2018 - 12:00

LONDON, Ontario, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V: SVA ) (OTCQB:SEOVF) (FSE:PSH), a clinical stage company developing regenerative medicine technologies for the treatment of chronic diseases [...]

Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with oral semaglutide

22/02/2018 - 10:42

Bagsværd, Denmark, 22 February 2018 - Novo Nordisk today announced the headline results from PIONEER 1, the first phase 3a trial with oral semaglutide for treatment of adults with type 2 diabetes. Oral semaglutide is a [...]

Corline Biomedical AB: Publicerar bokslutskommuniké för 2017

22/02/2018 - 08:48

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för räkenskapsåret 2017. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida ( www.corline.se ) [...]

LIDDS presenterar bokslutskommuniké 2017

22/02/2018 - 08:30

BOKSLUTSKOMMUNIKÉ 2017 FJÄRDE KVARTALET - OKTOBER - DECEMBER 2017 Nettoomsättningen uppgick till 0,4 (0,0) KSEK Kostnaderna uppgick till 2,5 (2,1) MSEK Resultatet före och efter skatt uppgick till -2,2 (-2,1) MSEK [...]

Ossur Hf : Final agenda and proposals for the Annual General Meeting 8 March 2018

22/02/2018 - 08:01

Announcement no. 12/2018 Reykjavik, 22 February 2018 Final agenda and proposals Enclosed is the final agenda and proposals for Össur's Annual General Meeting, to be held on Thursday 8 March 2018. The meeting will be [...]

Financière de Tubize SA: Annual financial Report

22/02/2018 - 08:01

Press release 22 February 2018 - 8:00h CET FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: Anne Sophie Pijcke, directeur, aspijcke@icloud.com Annual financial report 2017 Regulated [...]

Financière de Tubize SA: Rapport financier annuel

22/02/2018 - 08:01

Communiqué de presse 22 février 2018 - 8:00h CET FINANCIERE DE TUBIZE SA Allée de la Recherche 60, 1070 Bruxelles Contact: Anne Sophie Pijcke, directeur, aspijcke@icloud.com Rapport financier annuel 2017 Information [...]

William Demant Holding A/S: Annual Report 2017

22/02/2018 - 07:48

Company announcement no 2018-02 22 February 2018 Publication of Annual Report 2017 Organic growth of 9% in Group revenue, with strong performances by all business activities Hearing aid wholesale generated organic [...]

Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation

22/02/2018 - 07:16

Ultibro ® Breezhaler ® provided significant improvements in cardiac and lung function in COPD patients with lung hyperinflation, compared to placebo CLAIM is the first study to investigate the effect of dual [...]

NEOVACS STRENGTHENS ITS INTELLECTUAL PROPERTY IN THE USA

22/02/2018 - 07:01

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS STRENGTHENS ITS INTELLECTUAL PROPERTY IN THE USA This patent covers IFNalpha Kinoid and its application in all diseases related to an overproduction of IFNalpha [...]

NÉOVACS RENFORCE SA PROPRIÉTÉ INTELLECTUELLE AUX ÉTATS-UNIS

22/02/2018 - 07:01

COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE NÉOVACS RENFORCE SA PROPRI É T É INTELLECTUELLE AUX ÉTATS-UNIS Ce brevet porte sur l'IFNalpha Kinoïde et son utilisation dans les maladies liées à la [...]